The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Growth Factor Receptor ◽

Dual Phase ◽

Pet Ct ◽

Epidermal Growth ◽

18F Fdg ◽

Fdg Pet Ct ◽

The Relationship

Primary metabolic tumor volume from 18F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000001274 ◽

2020 ◽

Vol 41 (11) ◽

pp. 1210-1217

Author(s):

Xuhe Liao ◽

Yonggang Cui ◽

Xueqi Chen ◽

Lijuan Di ◽

Zhenghao Tong ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tumor Volume ◽

Growth Factor Receptor ◽

Metabolic Tumor Volume ◽

Pet Ct ◽

Epidermal Growth ◽

18F Fdg ◽

Fdg Pet Ct

Correlations Study Between 18F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma

Frontiers in Oncology ◽

10.3389/fonc.2019.00589 ◽

2019 ◽

Vol 9 ◽

Cited By ~ 2

Author(s):

Bin Yang ◽

Qing gen Wang ◽

Mengjie Lu ◽

Yingqian Ge ◽

Yu jun Zheng ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Fdg Pet ◽

Growth Factor Receptor ◽

Mutation Status ◽

Pet Ct ◽

Epidermal Growth ◽

18F Fdg ◽

Fdg Pet Ct

18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

Journal of Nuclear Medicine ◽

10.2967/jnumed.111.095257 ◽

2011 ◽

Vol 52 (11) ◽

pp. 1684-1689 ◽

Cited By ~ 52

Author(s):

M. R. Benz ◽

K. Herrmann ◽

F. Walter ◽

E. B. Garon ◽

K. L. Reckamp ◽

...

Keyword(s):

Growth Factor ◽

Growth Factor Receptor ◽

Pet Ct ◽

Epidermal Growth ◽

18F Fdg ◽

Treatment Responses ◽

Fdg Pet Ct ◽

Monitoring Treatment ◽

Receptor Inhibitor

Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer

Applied Immunohistochemistry & Molecular Morphology ◽

10.1097/pai.0000000000000525 ◽

2019 ◽

Vol 27 (1) ◽

pp. 1-7 ◽

Cited By ~ 1

Author(s):

Nosaibah Hariri ◽

Farnaz Hasteh ◽

Vighnesh Walavalkar ◽

Andres A. Roma ◽

Oluwole Fadare

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Progesterone Receptor ◽

Growth Factor Receptor ◽

Human Epidermal Growth Factor ◽

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Current Medical Research and Opinion ◽

10.1185/03007995.2016.1157060 ◽

2016 ◽

Vol 32 (5) ◽

pp. 959-965 ◽

Cited By ~ 11

Author(s):

T. Bell ◽

J.P. Crown ◽

I. Lang ◽

H. Bhattacharyya ◽

G. Zanotti ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Daily Activities ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Molybdenum Target X-Ray Features and Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 in Invasive Breast Cancer

International Journal of General Medicine ◽

10.2147/ijgm.s314055 ◽

2021 ◽

Vol Volume 14 ◽

pp. 2777-2783

Author(s):

Gulijire Tailaiti ◽

Gulanbaier Maimaiti ◽

Youlituzi Aikeremu ◽

Batuer Tuerdi

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Progesterone Receptor ◽

Invasive Breast Cancer ◽

Growth Factor Receptor ◽

X Ray ◽

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

Molecular Medicine Reports ◽

10.3892/mmr.2018.8580 ◽

2018 ◽

Cited By ~ 1

Author(s):

Seung Taek Lim ◽

Ye Won Jeon ◽

Hongki Gwak ◽

Se Young Kim ◽

Young Jin Suh

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Breast Cancer Cells ◽

Growth Factor Receptor ◽

Anticancer Effects ◽

Epidermal Growth ◽

Positive Breast Cancer

Abstract PD8-08: A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1

10.1158/1538-7445.sabcs20-pd8-08 ◽

2021 ◽

Author(s):

Hannah M Linden ◽

Mario Campone ◽

Aditya Bardia ◽

Gary A Ulaner ◽

Alice Gosselin ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Cancer Therapies ◽

Anti Cancer ◽

Er Positive ◽

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05125-4 ◽

2019 ◽

Vol 174 (3) ◽

pp. 719-729 ◽

Cited By ~ 56

Author(s):

H. S. Rugo ◽

R. S. Finn ◽

V. Diéras ◽

J. Ettl ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.08.009 ◽

2020 ◽

Vol 20 (2) ◽

pp. e173-e180 ◽

Cited By ~ 3

Author(s):

Hope S. Rugo ◽

Richard S. Finn ◽

Karen Gelmon ◽

Anil A. Joy ◽

Nadia Harbeck ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Objective Response ◽

Growth Factor Receptor ◽

Progression Free Survival ◽

Survival Outcome ◽

Free Survival ◽